Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In a recent observational study, Kronbichler et al recorded 95 severe/life-threatening infections in 49 of 192 patients (25.5%) with associated vasculitides (AAV) within approximately 2 years following rituximab initiation.1 Respiratory tract infections were the most common infectious complications. In patients with a positive culture, opportunistic pathogens were frequently seen, though Pneumocystis jirovecii was identified in only one case.
Trimethoprim/sulfamethoxazole prophylaxis was administered in 73 of 192 patients (38.0%) and resulted in an impressive reduction in the risk of severe infectious complications by 70%. Approximately half of patients were treated with 480 mg or 960 mg on alternate days. The optimum prophylactic dose of trimethoprim/sulfamethoxazole in patients with non-HIV remains unknown. The current recommendations for the management of AAV encourage prophylaxis against P. jirovecii infection with trimethoprim/sulfamethoxazole 960 mg on alternate days or 480 mg daily in all patients being treated with cyclophosphamide, where not contraindicated.2 There is some evidence suggesting that a lower dose of trimethoprim/sulfamethoxazole may be equally effective and more safe than 480 mg daily. In a randomised controlled …
Contributors All authors contributed to preparation of manuscript.
Funding Russian Academic Excellence Project 5-100.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.